Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|December 19, 2013

Pfenex Awarded Anthrax Inspection

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Pfenex reported that Leidos Holdings (formerly SAIC) has awarded Pfenex a subcontract in support of the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and immune-enhancing adjuvant.  The prime contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to improve the efficacy of both anthrax and West Nile virus vaccines by formulating them with a novel adjuvant that stimulates immune responses. Under the subcontract with Leidos, Pfenex will provide its rPA, which will be evaluated in various formulations with a selected adjuvant, to optimize the breadth and longevity of immune responses generated against anthrax.

This is the third government-funded contract awarded to Pfenex for the development of an anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology.

Source: Pfenex


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.